Sirid has a wealth of expertise gained from her time as an immunology researcher at the University of Minnesota and the DNAX Research Institute (Palo Alto), followed by successful tenures in the San Francisco Bay Area, as a project leader and biopharma collaborations liaison at Abgenix (a human antibody therapeutics company specializing in oncology and inflammation) and Entelos (a dynamic systems modeling company). Most recently, she led the Marketing group and subsequently the R&D team at NeuroScience, Inc.

In addition to a PhD in cellular and molecular immunology, Sirid has a "green" MBA from the Presidio Graduate School, and is passionate about doing business sustainably - that's why this website is 100% wind-powered! 

Well-versed in the difficult decisions biopharma companies face every day, Sirid is professionally certified in Strategic Decision and Risk Management from Stanford University. She applied SDRM principles as part of a strategic planning team at Abgenix, generating recommendations that guided the executive team at a critical juncture in the company's growth.

Sirid is a skilled content marketing partner and excels in visual and written presentation of complex information. She continues to hone her scientific knowledge, writing skills, and team leadership as an on-call grant writing specialist at Tn Consulting, and as an on-call Scientific Review Officer with SRA International

personal website
 | linkedin | twitter

Fernando's career is marked by a series of prescient insights that have led to significant advances in our understanding of the cellular and molecular basis of human disease. In addition to his scientific acumen specializing in biophysics and protein structure, Fernando has a knack for looking across the artificial boundaries of scientific disciplines, applying a collaborative, multidisciplinary approach to discover answers in unexpected places. He is the author of over 130 publications that have been cited nearly 30,000 times to date.

Trained at Stanford University, UC-Berkeley, and UC-San Francisco, Fernando contributed to key cytokine and genomic discoveries at DNAX Research Institute in Palo Alto, and then applied his protein engineering expertise to drug discovery in oncology and immunology at Genentech. As the CSO at NeuroScience, Inc., Fernando explored the molecular conversation between neurological and immune systems to better diagnose and treat complex human disorders. Fernando currently serves as the Chief Technology Officer at bio-Techne, and is an adjunct professor at the University of Minnesota.

[View Fernando's success stories here - several are described in more detail  here.]

Google Scholar publication list linkedin | insights | successes

“In biotechnology, high development costs and limited resources mean that companies need to make sound strategic decisions about which programs to advance - and which paths to deprioritize.

You may not be able to avoid bad outcomes, but you can avoid bad decisions. Quality decisions rely, among other things, on having a shared sense of purpose, the correct frame, and appropriate scientific, business, and other information. This is how you can achieve good strategic decisions with a commitment to action. 

My combination of biology background, Stanford-based decision analysis training, business and marketing acumen, objectivity and team leadership skills can help move teams forward in our common goal of improving human health.”

“My strategy for revealing novel cellular regulatory pathways and pinpointing potential targets is highly computational at the front-end, followed by biochemical, structural and proteomic analysis. I’m particularly interested in how cell signaling networks respond to perturbations such as pathogens, diseases, and therapies.

By seeking to understand the mechanisms of action of cellular protein signaling networks, my approach has yielded unique insights and catalyzed new work in several areas of biology. There's huge opportunity for new drug development when we focus on the critical protein complexes gleaned from a wealth of interaction and proteomic data.”

Subpages (1): Cases